Targeting mitochondria for cancer therapy

Nature Reviews Drug Discovery

Volumn 9, Issue 6, 2010, Pages 447-464

  Fulda, Simone ^a   Galluzzi, Lorenzo ^b,c,d   Kroemer, Guido ^b,c,d  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b INSERM   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 3 [3' (1 ADAMANTYL) 4' HYDROXYBIPHENYL 4 YL]ACRYLIC ACID; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXEN 1 YLMETHYL] 1 PIPERAZINYL] N [4 [3 MORPHOLINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONYL]BENZAMIDE; 6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; ALPHA TOCOPHEROL DERIVATIVE; ALPHA TOCOPHEROL SUCCINATE; ANTINEOPLASTIC AGENT; ARQ 501; ARSENIC TRIOXIDE; BETA LAPACHONE; BETULIC ACID; BORTEZOMIB; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DIAZEPAM; DICHLOROACETIC ACID; ELESCLOMOL; EPIRUBICIN; GADOLINIUM TEXAPHYRIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90 INHIBITOR; JASMONIC ACID METHYL ESTER; LONIDAMINE; MENADIONE; OBATOCLAX; OBLIMERSEN; PARTHENOLIDE; RESVERATROL; RETINOIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANTIOXIDANT ACTIVITY; APOPTOSIS; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; CANCER PREVENTION; CANCER THERAPY; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLON CANCER; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; GLIOBLASTOMA; HUMAN; LUNG CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL PERMEABILITY; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL MEMBRANE PERMEABILITY; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MITOCHONDRIA; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; PYRROLES; REACTIVE OXYGEN SPECIES; STILBENES;

EID: 77953131908     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3137     Document Type: Review

References (239)

1. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
2. Fulda, S. Tumor resistance to apoptosis. Int. J. Cancer 124, 511-515 (2009).
3. Fulda, S. & Debatin, K. M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25, 4798-4811 (2006).
4. Kroemer, G., Galluzzi, L. & Brenner, C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 87, 99-163 (2007). (Pubitemid 46209992)
5. Galluzzi, L. et al. No death without life: vital functions of apoptotic effectors. Cell Death Differ. 15, 1113-1123 (2008).
6. Galluzzi, L. & Kroemer, G. Necroptosis: a specialized pathway of programmed necrosis. Cell 135, 1161-1163 (2008).
7. Golstein, P. & Kroemer, G. Cell death by necrosis: towards a molecular definition. Trends Biochem. Sci. 32, 37-43 (2007).
8. Gogvadze, V., Orrenius, S. & Zhivotovsky, B. Mitochondria in cancer cells: what is so special about them? Trends Cell Biol. 18, 165-173 (2008).
9. Bellance, N., Lestienne, P. & Rossignol, R. Mitochondria: from bioenergetics to the metabolic regulation of carcinogenesis. Front. Biosci. 14, 4015-4034 (2009).
10. Diehn, M. et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458, 780-783 (2009).
11. Kroemer, G. & Pouyssegur, J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13, 472-482 (2008).
12. Modica-Napolitano, J. S. & Singh, K. K. Mitochondrial dysfunction in cancer. Mitochondrion 4, 755-762 (2004).
13. Canter, J. A., Kallianpur, A. R., Parl, F. F. & Millikan, R. C. Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. Cancer Res. 65, 8028-8033 (2005).
14. Petros, J. A. et al. mtDNA mutations increase tumorigenicity in prostate cancer. Proc. Natl Acad. Sci. USA 102, 719-724 (2005).
15. Galluzzi, L. et al. Mitochondrial gateways to cancer. Mol. Aspects Med. 31, 1-20 (2010).
16. Armstrong, J. S. Mitochondrial medicine: pharmacological targeting of mitochondria in disease. Br. J. Pharmacol. 151, 1154-1165 (2007).
17. Galluzzi, L., Larochette, N., Zamzami, N. & Kroemer, G. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 25, 4812-4830 (2006).
18. Gogvadze, V., Orrenius, S. & Zhivotovsky, B. Mitochondria as targets for cancer chemotherapy. Semin. Cancer Biol. 19, 57-66 (2009).
19. Bouchier-Hayes, L., Munoz-Pinedo, C., Connell, S. & Green, D. R. Measuring apoptosis at the single cell level. Methods 44, 222-228 (2008).
20. Nakagawa, T. et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 434, 652-658 (2005).
21. Baines, C. P., Kaiser, R. A., Sheiko, T., Craigen, W. J. & Molkentin, J. D. Voltage-dependent anion channels are dispensable for mitochondrial- dependent cell death. Nature Cell Biol. 9, 550-555 (2007).
22. Galluzzi, L. & Kroemer, G. Mitochondrial apoptosis without VDAC. Nature Cell Biol. 9, 487-489 (2007).
23. Kokoszka, J. E. et al. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature 427, 461-465 (2004).
24. Majewski, N. et al. Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol. Cell 16, 819-830 (2004).
25. Zamora, M., Granell, M., Mampel, T. & Vinas, O. Adenine nucleotide translocase 3 (ANT3) overexpression induces apoptosis in cultured cells. FEBS Lett. 563, 155-160 (2004).
26. Bauer, M. K., Schubert, A., Rocks, O. & Grimm, S. Adenine nucleotide translocase-1, a component of the permeability transition pore, can dominantly induce apoptosis. J. Cell Biol. 147, 1493-1502 (1999).
27. Le Bras., M. et al. Chemosensitization by knockdown of adenine nucleotide translocase-2. Cancer Res. 66, 9143-9152 (2006).
28. Marzo, I. et al. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science 281, 2027-2031 (1998).
29. Belzacq, A. S. et al. Bcl-2 and Bax modulate adenine nucleotide translocase activity. Cancer Res. 63, 541-546 (2003).
30. Shen, Q. et al. Adenine nucleotide translocator cooperates with core cell death machinery to promote apoptosis in Caenorhabditis elegans. Mol. Cell Biol. 29, 3881-3893 (2009).
31. Zhivotovsky, B., Galluzzi, L., Kepp, O. & Kroemer, G. Adenine nucleotide translocase: a component of the phylogenetically conserved cell death machinery. Cell Death Differ. 16, 1419-1425 (2009).
32. Don, A. S. et al. A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell 3, 497-509 (2003).
33. Belzacq, A. S. et al. Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437. Oncogene 20, 7579-7587 (2001).
34. Oudard, S. et al. Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. J. Neurooncol. 63, 81-86 (2003).
35. Dogliotti, L. et al. Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial. J. Clin. Oncol. 14, 1165-1172 (1996).
36. Papaldo, P. et al. Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. J. Clin. Oncol. 21, 3462-3468 (2003).
37. Lehenkari, P. P. et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol. Pharmacol. 61, 1255-1262 (2002).
38. Diel, I. J. et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann. Oncol. 19, 2007-2011 (2008).
39. Green, J. R. Antitumor effects of bisphosphonates. Cancer 97, 840-847 (2003).
40. Tang, X. et al. Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1α/VEGF signaling pathways in human breast cancer cells. Int. J. Cancer 126, 90-103 (2010).
41. Slack, J. L. & Rusiniak, M. E. Current issues in the management of acute promyelocytic leukemia. Ann. Hematol. 79, 227-238 (2000).
42. Marchetti, P. et al. The novel retinoid 6-[3-(1-adamantyl)-4- hydroxyphenyl]-2-naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus. Cancer Res. 59, 6257-6266 (1999).
43. Notario, B., Zamora, M., Vinas, O. & Mampel, T. All-trans-retinoic acid binds to and inhibits adenine nucleotide translocase and induces mitochondrial permeability transition. Mol. Pharmacol. 63, 224-231 (2003).
44. Parrella, E. et al. Antitumor activity of the retinoid-related molecules (E)-3-(4′-hydroxy-3′-adamantylbiphenyl-4-yl)acrylic acid (ST1926) and 6-[3-(1-adamantyl)-4-hydroxy phenyl]-2-naphthalene carboxylic acid (CD437) in F9 teratocarcinoma: role of retinoic acid receptor γ and retinoid-independent pathways. Mol. Pharmacol. 70, 909-924 (2006).
45. Sala, F. et al. Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of ST1926, a novel oral antitumor agent, adamantyl retinoid derivative, in plasma of patients in a Phase I study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877, 3118-3126 (2009).
46. Maaser, K. et al. Up-regulation of the peripheral benzodiazepine receptor during human colorectal carcinogenesis and tumor spread. Clin. Cancer Res. 11, 1751-1756 (2005). (Pubitemid 40471836)
47. Galiegue, S., Casellas, P., Kramar, A., Tinel, N. & Simony-Lafontaine, J. Immunohistochemical assessment of the peripheral benzodiazepine receptor in breast cancer and its relationship with survival. Clin. Cancer Res. 10, 2058-2064 (2004).
48. L and Mcl-1 expressing human cholangiocarcinoma cells. Gut 51, 556-561 (2002).
49. Decaudin, D. et al. Peripheral benzodiazepine receptor ligands reverse apoptosis resistance of cancer cells in vitro and in vivo. Cancer Res. 62, 1388-1393 (2002).
50. Gonzalez-Polo, R. A. et al. PK11195 potently sensitizes to apoptosis induction independently from the peripheral benzodiazepin receptor. Oncogene 24, 7503-7513 (2005).
51. Walter, R. B. et al. PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism. Blood 106, 3584-3593 (2005).
52. Palmeira, C. M. & Wallace, K. B. Benzoquinone inhibits the voltage-dependent induction of the mitochondrial permeability transition caused by redox-cycling naphthoquinones. Toxicol. Appl. Pharmacol. 143, 338-347 (1997).
53. Petronilli, V. et al. The voltage sensor of the mitochondrial permeability transition pore is tuned by the oxidation-reduction state of vicinal thiols. Increase of the gating potential by oxidants and its reversal by reducing agents. J. Biol. Chem. 269, 16638-16642 (1994).
54. Costantini, P. et al. Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis. Oncogene 19, 307-314 (2000).
55. Lim, D. et al. Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy. Invest. New Drugs 23, 235-239 (2005).
56. Sarin, S. K. et al. High dose vitamin K3 infusion in advanced hepatocellular carcinoma. J. Gastroenterol. Hepatol. 21, 1478-1482 (2006).
57. Magda, D. & Miller, R. A. Motexafin gadolinium: a novel redox active drug for cancer therapy. Semin. Cancer Biol. 16, 466-476 (2006).
58. Mehta, M. P. et al. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int. J. Radiat. Oncol. Biol. Phys. 73, 1069-1076 (2009).
59. Bradley, K. A. et al. Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study. Neuro Oncol. 10, 752-758 (2008).
60. Bey, E. A. et al. An NQO1-and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by β-lapachone. Proc. Natl Acad. Sci. USA 104, 11832-11837 (2007).
61. Maeda, H. et al. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and l-buthionine-sulfoximine. Cell Death Differ. 11, 737-746 (2004).
62. Dragovich, T. et al. Phase I trial of imexon in patients with advanced malignancy. J. Clin. Oncol. 25, 1779-1784 (2007).
63. Moulder, S. et al. A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. Invest. New Drugs 6 Jun 2009 (doi:10.1007/s10637-009-9273-1).
64. Trachootham, D. et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanate. Cancer Cell 10, 241-252 (2006).
65. Xiao, D. et al. Phenethyl isothiocyanate-induced apoptosis in PC-3 human prostate cancer cells is mediated by reactive oxygen species-dependent disruption of the mitochondrial membrane potential. Carcinogenesis 27, 2223-2234 (2006).
66. Alexandre, J. et al. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J. Natl Cancer Inst. 98, 236-244 (2006).
67. Huang, P., Feng, L., Oldham, E. A., Keating, M. J. & Plunkett, W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407, 390-395 (2000).
68. Wood, L. et al. Inhibition of superoxide dismutase by 2-methoxyoestradiol analogues and oestrogen derivatives: structure-activity relationships. Anticancer Drug Des. 16, 209-215 (2001).
69. 2-mediated oxidation and inactivation of phosphatases in growth factor signaling. Proc. Natl Acad. Sci. USA 105, 7147-7152 (2008).
70. Lu, J., Chew, E. H. & Holmgren, A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc. Natl Acad. Sci. USA 104, 12288-12293 (2007).
71. Tuma, R. S. Reactive oxygen species may have antitumor activity in metastatic melanoma. J. Natl Cancer Inst. 100, 11-12 (2008).
72. Matei, D. et al. Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Gynecol. Oncol. 11 5, 90-96 (2009).
73. Tevaarwerk, A. J. et al. Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies. Clin. Cancer Res. 15, 1460-1465 (2009).
74. Rajkumar, S. V. et al. Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. Clin. Cancer Res. 13, 6162-6167 (2007).
75. Sweeney, C. et al. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin. Cancer Res. 11, 6625-6633 (2005).
76. O'Day, S. et al. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J. Clin. Oncol. 27, 5452-5458 (2009).
77. Berkenblit, A. et al. Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. Clin. Cancer Res. 13, 584-590 (2007).
78. Chipuk, J. E., Bouchier-Hayes, L. & Green, D. R. Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario. Cell Death Differ. 13, 1396-1402 (2006).
79. Willis, S. N. & Adams, J. M. Life in the balance: how BH3-only proteins induce apoptosis. Curr. Opin. Cell Biol. 17, 617-625 (2005).
80. Lovell, J. F. et al. Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax. Cell 135, 1074-1084 (2008).
81. Leu, J. I., Dumont, P., Hafey, M., Murphy, M. E. & George, D. L. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nature Cell Biol. 6, 443-450 (2004).
82. Chipuk, J. E. et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303, 1010-1014 (2004).
83. Gavathiotis, E. et al. BAX activation is initiated at a novel interaction site. Nature 455, 1076-1081 (2008).
84. Bellot, G. et al. TOM22, a core component of the mitochondria outer membrane protein translocation pore, is a mitochondrial receptor for the proapoptotic protein Bax. Cell Death Differ. 14, 785-794 (2007).
85. Ross, K., Rudel, T. & Kozjak-Pavlovic, V. TOM-independent complex formation of Bax and Bak in mammalian mitochondria during TNFα-induced apoptosis. Cell Death Differ. 16, 697-707 (2009).
86. Rostovtseva, T. K. et al. Bax activates endophilin B1 oligomerization and lipid membrane vesiculation. J. Biol. Chem. 284, 34390-34399 (2009).
87. Kuwana, T. et al. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 111, 331-342 (2002).
88. Lucken-Ardjomande, S., Montessuit, S. & Martinou, J. C. Contributions to Bax insertion and oligomerization of lipids of the mitochondrial outer membrane. Cell Death Differ. 15, 929-937 (2008).
89. Cipolat, S. et al. Mitochondrial rhomboid PARL regulates cytochrome c release during apoptosis via OPA1-dependent cristae remodeling. Cell 126, 163-175 (2006).
90. Frezza, C. et al. OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion. Cell 126, 177-189 (2006).
91. Lessene, G., Czabotar, P. E. & Colman, P. M. BCL-2 family antagonists for cancer therapy. Nature Rev. Drug Discov. 7, 989-1000 (2008).
92. Vogler, M., Dinsdale, D., Dyer, M. J. & Cohen, G. M. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ. 16, 360-367 (2009).
93. Vogler, M. et al. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ. 16, 1030-1039 (2009).
94. Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677-681 (2005).
95. Chen, S., Dai, Y., Harada, H., Dent, P. & Grant, S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res. 67, 782-791 (2007).
96. Konopleva, M. et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10, 375-388 (2006).
97. Mason, K. D. et al. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc. Natl Acad. Sci. USA 105, 17961-17966 (2008).
98. van Delft, M. F. et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10, 389-399 (2006).
99. Kang, M. H. et al. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 11 0, 2057-2066 (2007).
100. Kutuk, O. & Letai, A. Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res. 68, 7985-7994 (2008).
101. Hann, C. L. et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res. 68, 2321-2328 (2008).
102. Tagscherer, K. E. et al. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 27, 6646-6656 (2008).
103. + leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc. Natl Acad. Sci. USA 103, 14907-14912 (2006).
104. Kuroda, J. et al. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Differ. 14, 1667-1677 (2007).
105. Kohl, T. M. et al. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia 21, 1763-1772 (2007).
106. Cragg, M. S., Kuroda, J., Puthalakath, H., Huang, D. C. & Strasser, A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med. 4, e316 (2007).
107. Gong, Y. et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med. 4, e294 (2007).
108. Cragg, M. S. et al. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J. Clin. Invest. 11 8, 3651-3659 (2008).
109. Paoluzzi, L. et al. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 11 2, 2906-2916 (2008).
110. Miller, L. A. et al. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. J. Invest. Dermatol. 129, 964-971 (2009).
111. Whitecross, K. F. et al. Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood 11 3, 1982-1991 (2009).
112. Huang, S. & Sinicrope, F. A. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res. 68, 2944-2951 (2008).
113. Song, J. H., Kandasamy, K. & Kraft, A. S. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J. Biol. Chem. 283, 25003-25013 (2008).
114. Mason, K. D. et al. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia 23, 2034-2041 (2009).
115. Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421-3428 (2008).
116. Lock, R. et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr. Blood Cancer 50, 1181-1189 (2008). (Pubitemid 351555542)
117. Shoemaker, A. R. et al. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res. 66, 8731-8739 (2006).
118. Lynn, A. & Jones, L. Gossypol and some other terpenoids, flavonoids, and phenols that affect quality of cottonseed protein. Am. Oil Chemists Soc. 56, 727-730 (1979).
119. Azmi, A. S. & Mohammad, R. M. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J. Cell Physiol. 218, 13-21 (2009).
120. Liu, G. et al. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin. Cancer Res. 15, 3172-3176 (2009).
121. Kitada, S. et al. Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). Blood 111, 3211-3219 (2008).
122. Nguyen, M. et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc. Natl Acad. Sci. USA 104, 19512-19517 (2007).
123. Trudel, S. et al. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 109, 5430-5438 (2007).
124. Perez-Galan, P., Roue, G., Villamor, N., Campo, E. & Colomer, D. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 109, 4441-4449 (2007).
125. Konopleva, M. et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 68, 3413-3420 (2008).
126. O'Brien, S. M. et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 11 3, 299-305 (2009).
127. Schimmer, A. D. et al. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin. Cancer Res. 14, 8295-8301 (2008).
128. Wang, J. L. et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Natl Acad. Sci. USA 97, 7124-7129 (2000).
129. Manero, F. et al. The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Res. 66, 2757-2764 (2006).
130. Moulder, S. L. et al. Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clin. Cancer Res. 14, 7909-7916 (2008).
131. O'Brien, S. et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J. Clin. Oncol. 25, 1114-1120 (2007).
132. Rheingold, S. R. et al. Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study. J. Clin. Oncol. 25, 1512-1518 (2007).
133. Rudin, C. M. et al. Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. J. Clin. Oncol. 26, 870-876 (2008).
134. Chanan-Khan, A. A. et al. Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. Leuk. Lymphoma 50, 559-565 (2009).
135. Simons, A. L., Ahmad, I. M., Mattson, D. M., Dornfeld, K. J. & Spitz, D. R. 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res. 67, 3364-3370 (2007).
136. Pastorino, J. G., Hoek, J. B. & Shulga, N. Activation of glycogen synthase kinase 3β disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res. 65, 10545-10554 (2005).
137. Chiara, F. et al. Hexokinase II detachment from mitochondria triggers apoptosis through the permeability transition pore independent of voltage-dependent anion channels. PLoS One 3, e1852 (2008).
138. Galluzzi, L., Kepp, O., Tajeddine, N. & Kroemer, G. Disruption of the hexokinase-VDAC complex for tumor therapy. Oncogene 27, 4633-4635 (2008).
139. Goldin, N. et al. Methyl jasmonate binds to and detaches mitochondria-bound hexokinase. Oncogene 27, 4636-4643 (2008).
140. Kim, W. et al. Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma. Mol. Cancer Ther. 6, 2554-2562 (2007).
141. Cao, X. et al. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor. Clin. Cancer Res. 14, 1831-1839 (2008).
142. Chen, Z., Zhang, H., Lu, W. & Huang, P. Role of mitochondria- associated hexokinase II in cancer cell death induced by 3-bromopyruvate. Biochim. Biophys. Acta 1787, 553-560 (2009).
143. + channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11, 37-51 (2007)
144. Fantin, V. R., St-Pierre, J. & Leder, P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9, 425-434 (2006).
145. Hatzivassiliou, G. et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8, 311-321 (2005).
146. Wellen, K. E. et al. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 324, 1076-1080 (2009).
147. Beckers, A. et al. Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res. 67, 8180-8187 (2007).
148. Carvalho, M. A. et al. Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model. Int. J. Cancer 123, 2557-2565 (2008).
149. Mootha, V. K. et al. Integrated analysis of protein composition, tissue diversity, and gene regulation in mouse mitochondria. Cell 11 5, 629-640 (2003).
150. Kang, B. H. et al. Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell 131, 257-270 (2007).
151. Wright, G. L. et al. VEGF stimulation of mitochondrial biogenesis: requirement of AKT3 kinase. FASEB J. 22, 3264-3275 (2008).
152. Plescia, J. et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 7, 457-468 (2005).
153. Gyurkocza, B. et al. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J. Natl Cancer Inst. 98, 1068-1077 (2006).
154. Kang, B. H. et al. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J. Clin. Invest. 11 9, 454-464 (2009).
155. Rodina, A. et al. Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer. Nature Chem. Biol. 3, 498-507 (2007).
156. Caldas-Lopes, E. et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc. Natl Acad. Sci. USA 106, 8368-8373 (2009).
157. Paduch, R., Kandefer-Szerszen, M., Trytek, M. & Fiedurek, J. Terpenes: substances useful in human healthcare. Arch. Immunol. Ther. Exp. (Warsz) 55, 315-327 (2007).
158. Liby, K. T., Yore, M. M. & Sporn, M. B. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nature Rev. Cancer 7, 357-369 (2007).
159. Cichewicz, R. H. & Kouzi, S. A. Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. Med. Res. Rev. 24, 90-114 (2004).
160. Fulda, S. et al. Betulinic acid triggers CD95 (APO-1/Fas)-and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res. 57, 4956-4964 (1997).
161. Fulda, S. et al. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J. Biol. Chem. 273, 33942-33948 (1998).
162. Fulda, S., Susin, S. A., Kroemer, G. & Debatin, K. M. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res. 58, 4453-4460 (1998). (Pubitemid 28450051)
163. Andre, N. et al. Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells. FEBS Lett. 532, 256-260 (2002).
164. Wick, W., Grimmel, C., Wagenknecht, B., Dichgans, J. & Weller, M. Betulinic acid-induced apoptosis in glioma cells: A sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing. J. Pharmacol. Exp. Ther. 289, 1306-1312 (1999).
165. Tan, Y., Yu, R. & Pezzuto, J. M. Betulinic acid-induced programmed cell death in human melanoma cells involves mitogen-activated protein kinase activation. Clin. Cancer Res. 9, 2866-2875 (2003).
166. Selzer, E. et al. Effects of betulinic acid alone and in combination with irradiation in human melanoma cells. J. Invest. Dermatol. 11 4, 935-940 (2000).
167. Selzer, E. et al. Betulinic acid-induced Mcl-1 expression in human melanoma\mode of action and functional significance. Mol. Med. 8, 877-884 (2002).
168. Thurnher, D. et al. Betulinic acid: a new cytotoxic compound against malignant head and neck cancer cells. Head Neck 25, 732-740 (2003).
169. Fulda, S. & Debatin, K. M. Betulinic acid induces apoptosis through a direct effect on mitochondria in neuroectodermal tumors. Med. Pediatr. Oncol. 35, 616-618 (2000).
170. Meng, R. D. & El-Deiry, W. S. p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. Exp. Cell Res. 262, 154-169 (2001).
171. Salti, G. I. et al. Betulinic acid reduces ultraviolet-C-induced DNA breakage in congenital melanocytic naeval cells: evidence for a potential role as a chemo-preventive agent. Melanoma Res. 11, 99-104 (2001).
172. Zuco, V. et al. Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett. 175, 17-25 (2002).
173. Lagouge, M. et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1a. Cell 127, 1109-1122 (2006).
174. Gledhill, J. R., Montgomery, M. G., Leslie, A. G. & Walker, J. E. Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. Proc. Natl Acad. Sci. USA 104, 13632-13637 (2007).
175. Tinhofer, I. et al. Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2. FASEB J. 15, 1613-1615 (2001).
176. Chen, C. et al. Mitochondrial ATP synthasome: three-dimensional structure by electron microscopy of the ATP synthase in complex formation with carriers for Pi and ADP/ATP. J. Biol. Chem. 279, 31761-31768 (2004).
177. Biasutto, L. et al. Development of mitochondria-targeted derivatives of resveratrol. Bioorg Med. Chem. Lett. 18, 5594-5597 (2008).
178. Jeong, S. H. et al. A novel resveratrol derivative, HS1793, overcomes the resistance conferred by Bcl-2 in human leukemic U937 cells. Biochem. Pharmacol. 77, 1337-1347 (2009).
179. Morrison, D. K. The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol. 19, 16-23 (2009).
180. Korsmeyer, S. J. BCL-2 gene family and the regulation of programmed cell death. Cancer Res. 59, 1693s-1700s (1999).
181. Boocock, D. J. et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev. 16, 1246-1252 (2007).
182. Constantinou, C, Papas, A. & Constantinou, A. I. Vitamin E and cancer: an insight into the anticancer activities of vitamin E isomers and analogs. Int. J. Cancer 123, 739-752 (2008).
183. Zhao, Y, Neuzil, J. & Wu, K. Vitamin E analogues as mitochondria-targeting compounds: from the bench to the bedside? Mol. Nutr. Food Res. 53, 129-139 (2009).
184. Jia, L, Yu, W., Wang, P., Sanders, B. G. & Kline, K. In vivo and in vitro studies of anticancer actions of ct-TEA for human prostate cancer cells. Prostate 68, 849-860 (2008).
185. Hahn, T et al. Dietary administration of the proapoptotic vitamin E analogue ct-tocopheryloxyacetic acid inhibits metastatic murine breast cancer. Cancer Res. 66, 9374-9378 (2006).
186. Lawson, K. A. et al. Comparison of vitamin E derivatives a-TEA and VES in reduction of mouse mammary tumor burden and metastasis. Exp. Biol. Med. (Maywood) 229, 954-963 (2004).
187. Dong, L. F. et al. Alpha-tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II. Oncogene 27, 4324-4335 (2008).
188. Dong, L. F. et al. Suppression of tumor growth in vivo by the mitocan a-tocopheryl succinate requires respiratory complex II. Clin. Cancer Res. 15, 1593-1600 (2009).
189. Dong, L. F. et al. Vitamin E analogues inhibit angiogenesis by selective induction of apoptosis in proliferating endothelial cells: the role of oxidative stress. Cancer Res. 67, 11906-11913 (2007).
190. Neuzil, J. et al. Induction of cancer cell apoptosis by a-tocopheryl succinate: molecular pathways and structural requirements. FASEB J. 15, 403-415 (2001).
191. Fariss, M. W, Nicholls-Grzemski, F. A., Tirmenstein, M. A. & Zhang, J. G. Enhanced antioxidant and cytoprotective abilities of vitamin E succinate is associated with a rapid uptake advantage in rat hepatocytes and mitochondria. Free Radic. Biol. Med. 31, 530-541 (2001).
192. Wright, M. E. et al. Effects of α-tocopherol and β-carotene supplementation on upper aerodigestive tract cancers in a large, randomized controlled trial. Cancer 109, 891-898 (2007).
193. Kim, J. H. et al. Susceptibility of cholangiocarcinoma cells to parthenolide-induced apoptosis. Cancer Res. 65, 6312-6320 (2005).
194. Steele, A. J. et al. The sesquiterpene lactone parthenolide induces selective apoptosis of B-chronic lymphocytic leukemia cells in vitro. Leukemia 20, 1073-1079 (2006).
195. Zhang, S., Ong, C. N. & Shen, H. M. Involvement of proapoptotic Bcl-2 family members in parthenolide-induced mitochondrial dysfunction and apoptosis. Cancer Lett. 211, 175-188 (2004).
196. Guzman, M. L. et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 110, 4427-4435 (2007).
197. Guzman, M. L. et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105, 4163-4169 (2005).
198. Pajak, B., Gajkowska, B. & Orzechowski, A. Molecular basis of parthenolide-dependent proapoptotic activity in cancer cells. Folia Histochem. Cytobiol. 46, 129-135 (2008).
199. Rosen, J. M. & Jordan, C. T. The increasing complexity of the cancer stem cell paradigm. Science 324, 1670-1673 (2009).
200. Smith, J., Ladi, E., Mayer-Proschel, M. & Noble, M. Redox state is a central modulator of the balance between self-renewal and differentiation in a dividing glial precursor cell. Proc. Natl Acad. Sci. USA 97, 10032-10037 (2000).
201. Tsatmali, M., Walcott, E. C. & Crossin, K. L. Newborn neurons acquire high levels of reactive oxygen species and increased mitochondrial proteins upon differentiation from progenitors. Brain Res. 1040, 137-150 (2005).
202. Ito, K. et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature 431, 997-1002 (2004).
203. Ito, K. et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nature Med. 12, 446-451 (2006).
204. Tothova, Z. et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 128, 325-339 (2007).
205. Miyamoto, K. et al. Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell 1, 101-112 (2007).
206. Simon, M. C. & Keith, B. The role of oxygen availability in embryonic development and stem cell function. Nature Rev. Mol. Cell Biol. 9, 285-296 (2008).
207. Brahimi-Horn, M. C., Chiche, J. & Pouyssegur, J. Hypoxia signalling controls metabolic demand. Curr. Opin. Cell Biol. 19, 223-229 (2007).
208. Warburg, O., Posener, K. & Negelein, E. Über den Stoffwechsel der Tumoren. Biochemische Zeitschrift 152, 319-344 (1924) (in German).
209. Miyamoto, S., Murphy, A. N. & Brown, J. H. Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II. Cell Death Differ. 15, 521-529 (2008).
210. Manning, B. D. & Cantley, L. C. AKT/PKB signaling: navigating downstream. Cell 129, 1261-1274 (2007).
211. Wang, H. Q. et al. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 24, 3574-3582 (2005).
212. Christofk, H. R., Vander Heiden, M. G., Wu, N., Asara, J. M. & Cantley, L. C. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452, 181-186 (2008).
213. Bensaad, K. et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107-120 (2006).
214. Matoba, S. et al. p53 regulates mitochondrial respiration. Science 312, 1650-1653 (2006).
215. Semenza, G. L. Life with oxygen. Science 318, 62-64 (2007).
216. Kim, J. W., Tchernyshyov, I., Semenza, G. L. & Dang, C. V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell. Metab. 3, 177-185 (2006).
217. Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L. & Denko, N. C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell. Metab. 3, 187-197 (2006).
218. Gottlieb, E. & Tomlinson, I. P. Mitochondrial tumour suppressors: a genetic and biochemical update. Nature Rev. Cancer 5, 857-866 (2005).
219. Murphy, M. P. Selective targeting of bioactive compounds to mitochondria. Trends Biotechnol. 15, 326-330 (1997).
220. Galluzzi, L. et al. Methods for the assessment of mitochondrial membrane permeabilization in apoptosis. Apoptosis 12, 803-813 (2007).
221. Yousif, L. F., Stewart, K. M. & Kelley, S. O. Targeting mitochondria with organelle-specific compounds: strategies and applications. Chembiochem 10, 1939-1950 (2009).
222. Ross, M. F., Filipovska, A., Smith, R. A., Gait, M. J. & Murphy, M. P. Cell-penetrating peptides do not cross mitochondrial membranes even when conjugated to a lipophilic cation: evidence against direct passage through phospholipid bilayers. Biochem. J. 383, 457-468 (2004).
223. Kelso, G. F. et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J. Biol. Chem. 276, 4588-4596 (2001).
224. Yousif, L. F., Stewart, K. M., Horton, K. L. & Kelley, S. O. Mitochondria-penetrating peptides: sequence effects and model cargo transport. Chembiochem 10, 2081-2088 (2009).
225. Neupert, W. & Herrmann, J. M. Translocation of proteins into mitochondria. Annu. Rev. Biochem. 76, 723-749 (2007).
226. Mukhopadhyay, A., Ni, L., Yang, C. S. & Weiner, H. Bacterial signal peptide recognizes HeLa cell mitochondrial import receptors and functions as a mitochondrial leader sequence. Cell. Mol. Life Sci. 62, 1890-1899 (2005).
227. Vestweber, D. & Schatz, G. DNA-protein conjugates can enter mitochondria via the protein import pathway. Nature 338, 170-172 (1989).
228. Srivastava, S. & Moraes, C. T. Manipulating mitochondrial DNA heteroplasmy by a mitochondrially targeted restriction endonuclease. Hum. Mol. Genet. 10, 3093-3099 (2001).
229. Horton, K. L., Stewart, K. M., Fonseca, S. B., Guo, Q. & Kelley, S. O. Mitochondria-penetrating peptides. Chem. Biol. 15, 375-382 (2008).
230. Maiti, K. K. et al. Guanidine-containing molecular transporters: sorbitol-based transporters show high intracellular selectivity toward mitochondria. Angew. Chem. Int. Ed. Engl. 46, 5880-5884 (2007).
231. Yamada, Y. et al. MITO-Porter: A liposome-based carrier system for delivery of macromolecules into mitochondria via membrane fusion. Biochim. Biophys. Acta 1778, 423-432 (2008).
232. Weissig, V. et al. DQAsomes: a novel potential drug and gene delivery system made from dequalinium. Pharm. Res. 15, 334-337 (1998).
233. Galluzzi, L. et al. Methods to dissect mitochondrial membrane permeabilization in the course of apoptosis. Methods Enzymol. 442, 355-374 (2008).
234. Deniaud, A. et al. Endoplasmic reticulum stress induces calcium-dependent permeability transition, mitochondrial outer membrane permeabilization and apoptosis. Oncogene 27, 285-299 (2008).
235. Yamada, Y., Akita, H., Kogure, K., Kamiya, H. & Harashima, H. Mitochondrial drug delivery and mitochondrial disease therapy\an approach to liposome-based delivery targeted to mitochondria. Mitochondrion 7, 63-71 (2007).
236. Sergeeva, A., Kolonin, M. G., Molldrem, J. J., Pasqualini, R. & Arap, W. Display technologies: application for the discovery of drug and gene delivery agents. Adv. Drug Deliv. Rev. 58, 1622-1654 (2006).
237. Pathania, D., Millard, M. & Neamati, N. Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Adv. Drug Deliv. Rev. 61, 1250-1275 (2009).
238. Kitada, S. et al. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J. Med. Chem. 46, 4259-4264 (2003).
239. Kirshner, J. R. et al. Elesclomol induces cancer cell apoptosis through oxidative stress. Mol. Cancer Ther.